Throat lozenge for the treatment of
View Patent ↗A lozenge for the treatment of Streptococcus Group A infections of the mouth, throat, and nasal passage is disclosed which comprises a lytic enzyme composition specific for Streptococcus Group A and a lozenge carrier for delivering the lytic enzyme.
1. A lozenge for treating an upper respiratory tract bacterial infection caused by Streptococcus Group A, wherein said lozenge is produced by the method of:
a) obtaining an effective amount of at least one lytic enzyme genetically coded for by at least one bacteriophage specific for Streptococcus Group A, said at least one specific lytic enzyme having the ability to specifically digest a cell wall of said Streptococcus Group A, and
b) mixing said at least one lytic enzyme produced in step (a) with a lozenge carrier for delivering said enzyme to a mouth, throat, or nasal passage.
2. The lozenge according to claim 1 , wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the mouth, throat, or nasal massage.
3. A lozenge for treating an upper respiratory tract bacterial infection caused by Streptococcus Group A, said lozenge comprising:
a) an effective amount of at least one lytic enzyme genetically coded for by at least one bacteriophage specific for said Streptococcus Group A, said at least one specific lytic enzyme having the ability to specifically digest a cell wall of said Streptococcus Group A, and
b) a lozenge carrier for delivering said enzyme to a mouth, throat, or nasal passage.
4. The lozenge according to claim 3 , wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.
5. The lozenge according to claim 4 , wherein the buffer maintains the pH of the composition at the range between 5.5 and 7.5.
6. The lozenge according to claim 4 , wherein said buffer comprises a reducing reagent.
7. The lozenge according to claim 6 , wherein said reducing reagent is dithiothreitol.
8. The lozenge according to claim 4 , wherein said buffer comprises a metal chelating reagent.
9. The lozenge according to claim 8 , wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.
10. The lozenge according to claim 4 , wherein said buffer is a citrate-phosphate buffer.
11. The lozenge according to claim 3 , further comprising a bactericidal or bacteriostatic agent as a preservative.
12. The lozenge according to claim 3 , wherein said lytic enzyme is lyophilized.
13. The lozenge according to claim 3 , wherein said at least one lytic enzyme is present in a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the mouth, throat or nasal passage.
14. The lozenge according to claim 3 , wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the mouth, throat, or nasal massage.
15. The lozenge according to claim 3 , wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.